Part II: Public Payers in the U.S. & Key International Markets

October 3, 2019 4:00 PM - 6:30 PM

MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139

This event, Part II in a three part series that will explore the value of health, will focus on Medicare and Medicaid in the U.S., existing access and reimbursement issues for innovative therapies and cures, proposed changes to those programs that could impact access and reimbursement, and barriers that exist to innovative payment models. The event will also consider those key international models of assessing value and determining access, how the global landscape is shifting, what the U.S. may be able to learn from them, and highlight emerging markets like China that are moving toward the realm of “must consider” when developing an international strategy. Speakers will share lessons learned and case studies around:

  • How Louisiana Medicaid cured its Hepatitis C population through an innovative payment model with Gilead Sciences 
  • How Biogen and Alnylam approached approvals abroad; lessons learned for navigating health technology assessment (HTA) consolidation in Europe
  • Why a US biotech partnered with a Chinese company to reach the large patient populations in China

We believe this issue is especially timely. We’re at an inflection point, with science that’s been tested for decades finally becoming a reality for patients and a payer system that has not caught up with this level of innovation. Myriad factors are combining to alter the status quo – with policymakers demanding action, and healthcare stakeholders agreeing that we must come up with real solutions. If we don’t come together and address the value equation as an industry and ensure patient access to all new therapies, government or other stakeholders will – and they will likely get it wrong. Download the Part II whitepaper

Drinks and appetizers will be provided. If you're not a MassBio member but are interested in attending, please email

Vice President, Business Development, BeiGene
John has over 20 years of business development, strategic transactions, and scientific experience in the pharmaceutical and biotechnology industries. John joined BeiGene in June 2019 as Vice President, Business Development and is primarily responsible for deal structuring and negotiating strategic partnerships. Prior to joining BeiGene, John was Vice President of Corporate and Business Development at rHEALTH LLC, where he led the corporate and business development strategy from 2017 to 2019. Prior to rHEALTH, John spent sixteen years with Boehringer Ingelheim Pharmaceuticals as Head of Strategic Transactions and Alliance Management located in Connecticut. In that role, he led a transaction team responsible for structuring, negotiating and managing global partnerships. He has an established track-record and experience with a broad array of deal structures across various therapeutic categories including, platform technologies, R&D collaborations, co-development and commercialization alliances, IP licenses, equity investments, and out-licensing arrangements. John began his business development career in 2000 at MedImmune and held various research roles of increasing responsibility with MedImmune, SmithKline Beecham Pharmaceuticals, and Allelix Biopharmaceuticals. John holds B.S. and M.S. degrees in Molecular Biology and Genetics from the University of Guelph, Canada, and an M.B.A.